Stock Market

Sun Pharma reports surprise Q2 loss of Rs 219 crore on one-time hit

   Download Android App    Share in      FullScreen   CheckVideos

Pharma major Sun Pharmaceutical on Tuesday posted a consolidated loss of Rs 218.82 crore for quarter ended September 30, on one-time loss of Rs 1,214.38 crore with respect to Modafinil antitrust litigation. Analysts in an ET NOW poll had estimated a profit of Rs 975 crore. The drug firm had posted a profit of Rs 912.12 crore in the corresponding quarter last year. Consolidated total revenue increased 4.32 per cent year-on-year to Rs 6,937.63 crore during the quarter under review against Rs 6,650.34 crore in the same period last year. Total expenditure jumped to Rs 5,962.46 crore in Q2FY19 over Rs 5,790.82 crore in Q2FY18. The company announced its financial results post market hours.

Earlier in the session, shares of Sun Pharmaceuticals closed 4.72 per cent down at Rs 561.70, while the BSE Sensex gained 0.95 per cent to 35,144.49. Ebitda rose to Rs 1,530.90 crore during the quarter under review against Rs 376 crore last year. For the quarter ended September 30, margins came in at 22.10 per cent against 19.90 per cent last year.




Unlimited Portal Access + Monthly Magazine - 12 issues-Publication from Jan 2021

Buy Our Merchandise (Peace Series)

 

Contribute US to Start Broadcasting


It's Voluntary! Take care of your Family, Friends and People around You First and later think about us. Its Fine if you dont wish to contribute and if you wish to contribute then think about the Homeless first and Feed them. We can survive with your wishes too :-). You can Buy our Merchandise too which are of the finest quality.

Debit/Credit/UPI

UPI/Debit/Credit

Paytm

STRIPE

Details
Category: Stock Market


21